Pharmagreen Biotech Stock Probability of Future Pink Sheet Price Finishing Under 0.000018
| PHBI Stock | USD 0 0.0001 5.88% |
Pharmagreen |
Pharmagreen Biotech Target Price Odds to finish below 0.000018
The tendency of Pharmagreen Pink Sheet price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to drop to $ 0.000018 or more in 90 days |
| 0 | 90 days | 0.000018 | near 1 |
Based on a normal probability distribution, the odds of Pharmagreen Biotech to drop to $ 0.000018 or more in 90 days from now is near 1 (This Pharmagreen Biotech probability density function shows the probability of Pharmagreen Pink Sheet to fall within a particular range of prices over 90 days) . Probability of Pharmagreen Biotech price to stay between $ 0.000018 and its current price of $0.0018 at the end of the 90-day period is about 23.47 .
Given the investment horizon of 90 days the pink sheet has the beta coefficient of 1.38 indicating as the benchmark fluctuates upward, the company is expected to outperform it on average. However, if the benchmark returns are projected to be negative, Pharmagreen Biotech will likely underperform. Moreover Pharmagreen Biotech has an alpha of 1.5833, implying that it can generate a 1.58 percent excess return over Dow Jones Industrial after adjusting for the inherited market risk (beta). Pharmagreen Biotech Price Density |
| Price |
Predictive Modules for Pharmagreen Biotech
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Pharmagreen Biotech. Regardless of method or technology, however, to accurately forecast the pink sheet market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the pink sheet market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Pharmagreen Biotech Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Pharmagreen Biotech is not an exception. The market had few large corrections towards the Pharmagreen Biotech's value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Pharmagreen Biotech, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Pharmagreen Biotech within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | 1.58 | |
β | Beta against Dow Jones | 1.38 | |
σ | Overall volatility | 0 | |
Ir | Information ratio | 0.12 |
Pharmagreen Biotech Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Pharmagreen Biotech for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Pharmagreen Biotech can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Pharmagreen Biotech is way too risky over 90 days horizon | |
| Pharmagreen Biotech has some characteristics of a very speculative penny stock | |
| Pharmagreen Biotech appears to be risky and price may revert if volatility continues | |
| Pharmagreen Biotech currently holds 119.47 K in liabilities. Pharmagreen Biotech has a current ratio of 0.1, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Pharmagreen Biotech until it has trouble settling it off, either with new capital or with free cash flow. So, Pharmagreen Biotech's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Pharmagreen Biotech sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Pharmagreen to invest in growth at high rates of return. When we think about Pharmagreen Biotech's use of debt, we should always consider it together with cash and equity. | |
| Net Loss for the year was (875.48 K) with profit before overhead, payroll, taxes, and interest of 0. | |
| Pharmagreen Biotech currently holds about 24.26 K in cash with (426.57 K) of positive cash flow from operations. | |
| Roughly 19.0% of the company outstanding shares are owned by corporate insiders |
Pharmagreen Biotech Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Pharmagreen Pink Sheet often depends not only on the future outlook of the current and potential Pharmagreen Biotech's investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Pharmagreen Biotech's indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 442.3 M | |
| Short Long Term Debt | 219.1 K | |
| Shares Float | 370 M |
Pharmagreen Biotech Technical Analysis
Pharmagreen Biotech's future price can be derived by breaking down and analyzing its technical indicators over time. Pharmagreen Pink Sheet technical analysis helps investors analyze different prices and returns patterns as well as diagnose historical swings to determine the real value of Pharmagreen Biotech. In general, you should focus on analyzing Pharmagreen Pink Sheet price patterns and their correlations with different microeconomic environments and drivers.
Pharmagreen Biotech Predictive Forecast Models
Pharmagreen Biotech's time-series forecasting models is one of many Pharmagreen Biotech's pink sheet analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models are widely used for non-stationary data. Non-stationary data are called the data whose statistical properties, e.g., the mean and standard deviation, are not constant over time, but instead, these metrics vary over time. This non-stationary Pharmagreen Biotech's historical data is usually called time series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the pink sheet market movement and maximize returns from investment trading.
Things to note about Pharmagreen Biotech
Checking the ongoing alerts about Pharmagreen Biotech for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for Pharmagreen Biotech help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
| Pharmagreen Biotech is way too risky over 90 days horizon | |
| Pharmagreen Biotech has some characteristics of a very speculative penny stock | |
| Pharmagreen Biotech appears to be risky and price may revert if volatility continues | |
| Pharmagreen Biotech currently holds 119.47 K in liabilities. Pharmagreen Biotech has a current ratio of 0.1, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Pharmagreen Biotech until it has trouble settling it off, either with new capital or with free cash flow. So, Pharmagreen Biotech's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Pharmagreen Biotech sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Pharmagreen to invest in growth at high rates of return. When we think about Pharmagreen Biotech's use of debt, we should always consider it together with cash and equity. | |
| Net Loss for the year was (875.48 K) with profit before overhead, payroll, taxes, and interest of 0. | |
| Pharmagreen Biotech currently holds about 24.26 K in cash with (426.57 K) of positive cash flow from operations. | |
| Roughly 19.0% of the company outstanding shares are owned by corporate insiders |
Other Information on Investing in Pharmagreen Pink Sheet
Pharmagreen Biotech financial ratios help investors to determine whether Pharmagreen Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Pharmagreen with respect to the benefits of owning Pharmagreen Biotech security.